top of page

BREAKING NEWS: FDA clears AEYE’s autonomous screening system for diabetic retinopathy featuring groundbreaking diagnostic accuracy, >99% imageability and using only one image per eye

Redefining Autonomous Diagnostic Screening

We’re applying our AI expertise to retinal imaging to deliver broad diagnostic screening solutions that address care gaps in primary care

AEYE Diagnostic Screening

AEYE Diagnostic Screening (AEYE-DS) utilizes Artificial Intelligence (AI) technology to diagnose diabetic retinopathy from retinal images.

First to be proven accurate on both a stationary desktop camera and a portable handheld camera

AEYE with TOPCON

AURORA AEYE

An image of the Optomed Aurora handheld fundus camera

NOT SOLD IN THE US

FDA Cleared
Topcon NW fundus camera with the AEYE System

CAUTION: Federal (US) law restricts this device to investigational use only.

icon of an eye with a target

Best-in-class Accuracy

Proven accurate in a prospecitve clinical trial

Desktop

93.0

91.4%

Sensitivity

Specificity

Handheld

93.6%

Specificity

91.9% 

Sensitivity

aeye_1 Icon Project-03.png

The Only Practical Solution

Requires one images per eye;

rarely requires dilation

handheld & desktop

1 Image

Per eye

Imageability

>99% 

Icon of a healthcare professional with a reimbursable report

Accessible

Enables point-of-care screening instead of referring to a specialist.

Reimbursement code

CPT 92229

Measure 117

HEDIS Quality Measure

Over 35M

people with diabetes in the US and 422M worldwide are at risk of sight-threatening diabetic retinopathy.

85%

of people with diabetes over 40 will develop diabetic retinopathy.

Why it matters

Screening Prevents Blindness

Accessible and affordable screening for diabetic retinopathy is vital to help ensure patients with diabetes receive sight-saving treatment.

Map of the United States with symbol of 50% and a message stating that 'only 15 to 50% of patients with diabetes in the US adhere to the recommended screening.
Only 15% to 50%

of patients with diabetes in the US adhere to the recommended screening.

Why It Matters

Screening prevents blindness

Accessible and affordable point-of-care screening for diabetic retinopathy is vital to help ensure people with diabetes receive sight-saving treatment.

Before

After

The first image shows the current diabetic retinopathy screening process where by a patient receives an annual referral for an eye exam and less than 50% adhere to the screening. In the second image the solution is shown where by a patient receives on-the-spot diagnosis during a GP visit and is then either cleared for 12 months due to negative result or referred to a specialist for treatment if the result is positive.
Our Problem.png

Benefits of
Point-of-Care Screening

Frame 6356194.png

Practical

Requires only one image per eye; rarely requires dilation

Frame 6356193.png

Accurate

Best-in-class efficacy proven in a pivotal prospective FDA study

Frame 6356192.png

Simple to operate

Can be operated by primary care personnel with no prior experience

Frame 6356093 (3).png

Reimbursable

Dedicated CPT code 92229

Frame 6356093.png

Closes Care Gaps

Closes the diabetic eye exam care gap for HEDIS/Star quality measures

FDAlogo.png

Diabetic Retinopathy 

Best-in-class accuracy

Published results

Diabetic retinopathy is the leading cause of blindness in working-age adults in the US.
 

Our FDA-cleared technology enables accessible early detection, which can save the sight of millions.

Our Mission

Autonomous comprehensive diagnostic screening for a broad range of diseases using retinal images

FDAlogo.png

Diabetic Retinopathy 

Best-in-class accuracy

Published results

Diabetic retinopathy is the leading cause of blindness in working-age adults in the US.
 

Our FDA-cleared technology enables accessible early detection, which can save the sight of millions.

Glaucoma 

Best-in-class accuracy

Published results

Glaucoma is the second most common cause of blindness worldwide.

Our algorithm enables early detection and accessible screening, encouraging timely and effective treatment. Our results are also the first to show high agreement with eye doctors.

Age-related Macular Degeneration (AMD)

Best-in-class accuracy

Publication coming soon

Age-related Macular Degeneration is an extremely common condition which impairs sharp central vision.

Our algorithm enables early detection, which can aid in dramatically slowing disease progression. Results for our best-in-class solution will be published imminently.

CAUTION: Federal (US) law restricts this device to investigational use only.

NOT SOLD IN THE US

See what people are saying about us